Farmacoriflessioni
Terapia farmacologica in urgenza
Pharmacological therapy for pediatric emergencies
Domenica Squillaci1, Cristina Tumminelli1, Idoya Molina Ruiz1, Lorenzo Calligaris2, Federico Poropat2, Egidio Barbi1,2, Alessandro Amaddeo2, Giorgio Cozzi2
1Università di Trieste
2IRCCS Materno-Infantile “Burlo Garofolo”, Trieste
Settembre 2022 - pagg. 441 -450 | DOI: 10.53126/MEB41441
Abstract
Emergency cases are rare events in the paediatric emergency department. Nevertheless, paediatricians working at the emergency department should be able to provide the appropriate pharmacological intervention. This retrospective study, performed at the paediatric emergency department of the Institute for Maternal and Child Health IRCCS “Burlo Garofolo” in Trieste (Italy), analysed 251 emergency cases. The most frequently reported emergencies were related to respiratory and neurological diseases. Oxygen, bronchodilators, fluids and anticonvulsants were the drugs most frequent-ly administered. The results were discussed according to the recent literature evidence.
Riassunto
Le emergenze pediatriche sono rare. Tuttavia, il pediatra deve conoscere e saper utilizzare quelli che sono gli interventi farmacologici appropriati in questo contesto assistenziale. Questo studio retrospettivo, svolto presso il Pronto Soccorso pediatrico dell’IRCCS Materno-Infantile “Burlo Garofolo” di Trieste, ha analizzato 251 casi di emergenza pediatrica. Le emergenze più frequentemente riportate sono state legate a malattie respiratorie e neurologiche. Ossigeno, broncodilatatori, fluidi e anticonvulsivanti sono stati i farmaci più frequentemente somministrati. In questo articolo discu-tiamo i risultati della nostra casistica in base alle attuali evidenze della letteratura.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet 2017;389(10065):211-24. doi: 10.1016/S0140-6736(16)30951-5.
2. Cozzi G, Pusceddu S, Mambelli L, Barbi E, Marchetti F. Le nuove linee guida sulla bronchiolite. Medico e Bambino 2015;34(6):369-75.
3. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013;2013(9):CD0000 52. doi: 10.1002/14651858.CD000052.pub3.
4. Barbi E, Petaros P, Lenhardt A, Longo G. Salbutamolo e cortisonici nell’accesso acuto d’asma: tutto scontato, ma non troppo. Medico e Bambino 2004;23:559-65.
5. Longo G, Maschio M, Panontin E, Marchetti F, Furcolo G, Quarantiello F. La gestione dell’accesso asmatico acuto in Pronto Soccorso (e non solo). Medico e Bambino 2014; 33:570-8.
6. Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev 2013;(8):CD000060. doi: 10.1002/ 14651858.CD000060.pub2.
7. Singhi S, Grover S, Bansal A, Chopra K. Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. Acta Paediatr 2014;103(12):1301-6. doi: 10.1111/apa.12780.
8. Su Z, Li R, Gai Z. Intravenous and nebulized magnesium sulfate for treating acute asthma in children: a systematic review and meta-analysis. Pediatr Emerg Care 2018;34 (6):390-5. doi: 10.1097/PEC.0000000000000 909.
9. Smith M, Iqbal S, Elliott TM, Everard M, Rowe BH. Corticosteroids for hospitalised children with acute asthma. Cochrane Database Syst Rev 2003;2003(2):CD002886. doi: 10.1002/14651858.CD002886.
10. Longo G. Il cortisone nel viral wheezing dell’età prescolare. Medico e Bambino 2018; 37(2):76-7.
11. Sánchez Fernández I, Gaínza-Lein M, Loddenkemper T. Nonintravenous rescue medications for pediatric status epilepticus: a cost-effectiveness analysis. Epilepsia 2017; 58(8):1349-59. doi: 10.1111/epi.13812.
12. Marchetti F, Rametta G, Ricciardelli P. Il midazolam in soluzione transmucosa orale. Medico e Bambino 2013;32(5):313-7.
13. Chhabra R, Gupta R, Gupta LK. Intranasal midazolam versus intravenous/rectal benzodiazepines for acute seizure control in children: a systematic review and meta-analysis. Epilepsy Behav 2021;125:108390. doi: 10.1016/j.yebeh.2021.108390.
14. Silbergleit R, Lowenstein D, Durkalski V, Conwit R; Neurological Emergency Treatment Trials (NETT) Investigators. RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics. Epilepsia 2011;52 Suppl 8(Suppl 8):45-7. doi: 10.1111/j.1528-1167.2011.03235.x.
15. Appleton R, Choonara I, Martland T, Phillips B, Scott R, Whitehouse W. The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party. Arch Dis Child 2000;83(5):415-9. doi: 10.1136/adc.83.5.415.
16. Dalziel SR, Borland ML, Furyk J, et al. PREDICT research network. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet 2019;393 (10186):2135-45. doi: 10.1016/S0140-6736 (19)30722-6.
17. Lyttle MD, Rainford NEA, Gamble C, et al. Paediatric Emergency Research in the United Kingdom & Ireland (PERUKI) collaborative. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019;393(10186):2125-34. doi: 10.1016/S0140-6736(19)30724-X.
18. Abdelgadir I, Hamud A, Kadri A, et al. Levetiracetam for convulsive status epilepticus in childhood: systematic review and meta-analysis. Arch Dis Child 2020 Oct 15:archdischild-2020-319573. doi: 10.1136/archdischild-2020-319573.
19. Chamberlain JM, Kapur J, Shinnar S, et al; Neurological Emergencies Treatment Trials; Pediatric Emergency Care Applied Research Network investigators. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet 2020;395(10231):1217-24. doi: 10.1016/S0140-6736(20)30611-5.
20. Höfler J, Trinka E. Intravenous ketamine in status epilepticus. Epilepsia 2018;59 Suppl 2:198-206. doi: 10.1111/epi.14480.
21. Bruno I. Utilizzo del fentanil endonasale nel trattamento del dolore acuto grave. Medico e Bambino 2012;31(6):390-1.
22. Cortellazzo Wiel L, Poropat F, Barbi E, Cozzi G. Is opioid analgesia superior to NSAID analgesia in children with musculoskeletal trauma? Arch Dis Child 2020;105 (12):1229-32. doi: 10.1136/archdischild-2020-319359.
23. Marzuillo P, Calligaris L, Amoroso S, Barbi E. Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children. Acta Paediatr 2018;107(4):560-7. doi: 10.1111/apa.14189.
24. Benini F, Congedi S, Scalfaro C, Barbi E, Podestà AF, per il Gruppo di Studio PIPER. Update sulla gestione del dolore del bambino in Pronto Soccorso. Medico e Bambino 2019;38(1):19-27.
25. Shein SL, Ferguson NM, Kochanek PM, et al. Effectiveness of pharmacological therapies for intracranial hypertension in children with severe traumatic brain injury. Results from an automated data collection system time-synched to drug administration. Pediatr Crit Care Med 2016;17(3):236-45. doi: 10.1097/PCC.0000000000000610.
26. Gantner D, Moore EM, Cooper DJ. Intravenous fluids in traumatic brain injury: what’s the solution? Curr Opin Crit Care 2014;20(4): 385-9. doi: 10.1097/MCC.0000000000000114.
27. Shi J, Tan L, Ye J, Hu L. Hypertonic saline and mannitol in patients with traumatic brain injury: a systematic and meta-analysis. Medicine (Baltimore) 2020;99(35):e21655. doi: 10.1097/MD.0000000000021655.
28. Kochanek PM, Adelson PD, Rosario BL, et al.; ADAPT Investigators. comparison of intracranial pressure measurements before and after hypertonic saline or mannitol treatment in children with severe traumatic brain injury. JAMA Netw Open 2022;5(3):e220891. doi: 10.1001/jamanetworkopen.2022.0891.
29. Marill KA, Wolfram S, Desouza IS, et al. Adenosine for wide-complex tachycardia: efficacy and safety. Crit Care Med 2009;37(9): 2512-8. doi: 10.1097/CCM.0b013e3181a 93661.
30. Quail MA, Till J. Question 3: does a higher initial dose of adenosine improve cardioversion rates in supraventricular tachycardia? Arch Dis Child 2012;97(2):177-9. doi: 10.1136/archdischild-2011-301079.
31. Richardson C, Silver ES. Management of supraventricular tachycardia in infants. Paediatr Drugs 2017;19(6):539-51. doi: 10.1007/ s40272-017-0254-0.
32. Postorivo S, Pusceddu S, Renzelli C, Francesconi R. Gestione della tachicardia parossistica sopraventricolare pediatrica: dai farmaci alla cardioversione elettrica in emergenza. Medico e Bambino pagine elettroniche 2017;20(4).
33. Mason J, Colwell CB, Grock A. Agitation crisis control. Ann Emerg Med 2018;72(4): 371-3. doi: 10.1016/j.annemergmed.2018.08. 004.
34. Gerson R, Malas N, Feuer V, Silver GH, Prasad R, Mroczkowski MM. Best practices for Evaluation and Treatment of Agitated children and adolescents (BETA) in the Emergency Department: consensus statement of the American Association for Emergency Psychiatry. West J Emerg Med 2019; 20(2):409-18. doi: 10.5811/westjem.2019.1. 41344.
35. Lin J, Figuerado Y, Montgomery A, et al. Efficacy of ketamine for initial control of acute agitation in the emergency department: A randomized study. Am J Emerg Med 2021; 44:306-11. doi: 10.1016/j.ajem.2020.04.013.
Corrispondenza: giorgio.cozzi@burlo.trieste.it